Drug firms stock prices hit by safety scares !!! ( London f.t.s.e )

[Guest guest]

http://www.network54.com/Forum/message?

forumid=281849 & messageid=1100892378

Drug firms hit by safety scares

Concerns about the health of drug companies after a warning from a

whistleblower at the US Food and Drug Administration (FDA) have hit

shares.

The FDA's Dr Graham warned that certain drugs from

AstraZeneca, Roche and GlaxoKline (GSK) needed further

regulatory attention.

AstraZeneca responded during the afternoon on Friday by insisting

the FDA had said it had no safety concerns.

AstraZeneca fell more than 10%, and GSK almost 4% by late afternoon

in London.

Dr Graham's warning came as he was speaking to the US Senate on

Thursday on Merck's banned drug Vioxx.

During his talk he cast doubt on the FDA's competence.

Dr Graham's list of drugs requiring further scrutiny from the Food

and Drug Administration included AstraZeneca's Crestor,

GlaxoKline's Serevent and Roche's Accutane.

In response, AstraZeneca said during Friday afternoon: " We have been

assured today at senior levels in the FDA that there is no concern

in relation to Crestor's safety " .

Glaxo says its quest is to " enable people to do more,

feel better and live longer "

Merrill Lynch, the US investment bank, noted that neither asthma

drug, Serevent, nor acne drug, Accutane, accounted for a big share

of their makers' profits.

But it expects cholesterol-cutting Crestor to make up 12% of

AstraZeneca's sales by 2008.

A forthcoming article in the US American Medical Association Review

is expected to cover the drug's kidney side-effects.

Safe and effective

Unethical behaviour by drug companies has been in the spotlight

after New York attorney general Eliot Spitzer fined GSK for

allegedly suppressing negative clinical trial data on Seroxat.

In a statement issued on Thursday GSK said it stands behind

Serevent, saying it is " safe and effective " .

It added that: " any issues concerning mortality...have been fully

considered by the FDA, resulting in a black box warning that was

included in the medicine's label " in August 2003.

http://news.bbc.co.uk/1/hi/business/4025001.stm

[Guest guest]

http://www.network54.com/Forum/message?

forumid=281849 & messageid=1100892378

Drug firms hit by safety scares

Concerns about the health of drug companies after a warning from a

whistleblower at the US Food and Drug Administration (FDA) have hit

shares.

The FDA's Dr Graham warned that certain drugs from

AstraZeneca, Roche and GlaxoKline (GSK) needed further

regulatory attention.

AstraZeneca responded during the afternoon on Friday by insisting

the FDA had said it had no safety concerns.

AstraZeneca fell more than 10%, and GSK almost 4% by late afternoon

in London.

Dr Graham's warning came as he was speaking to the US Senate on

Thursday on Merck's banned drug Vioxx.

During his talk he cast doubt on the FDA's competence.

Dr Graham's list of drugs requiring further scrutiny from the Food

and Drug Administration included AstraZeneca's Crestor,

GlaxoKline's Serevent and Roche's Accutane.

In response, AstraZeneca said during Friday afternoon: " We have been

assured today at senior levels in the FDA that there is no concern

in relation to Crestor's safety " .

Glaxo says its quest is to " enable people to do more,

feel better and live longer "

Merrill Lynch, the US investment bank, noted that neither asthma

drug, Serevent, nor acne drug, Accutane, accounted for a big share

of their makers' profits.

But it expects cholesterol-cutting Crestor to make up 12% of

AstraZeneca's sales by 2008.

A forthcoming article in the US American Medical Association Review

is expected to cover the drug's kidney side-effects.

Safe and effective

Unethical behaviour by drug companies has been in the spotlight

after New York attorney general Eliot Spitzer fined GSK for

allegedly suppressing negative clinical trial data on Seroxat.

In a statement issued on Thursday GSK said it stands behind

Serevent, saying it is " safe and effective " .

It added that: " any issues concerning mortality...have been fully

considered by the FDA, resulting in a black box warning that was

included in the medicine's label " in August 2003.

http://news.bbc.co.uk/1/hi/business/4025001.stm

[Guest guest]

http://www.network54.com/Forum/message?

forumid=281849 & messageid=1100892378

Drug firms hit by safety scares

Concerns about the health of drug companies after a warning from a

whistleblower at the US Food and Drug Administration (FDA) have hit

shares.

The FDA's Dr Graham warned that certain drugs from

AstraZeneca, Roche and GlaxoKline (GSK) needed further

regulatory attention.

AstraZeneca responded during the afternoon on Friday by insisting

the FDA had said it had no safety concerns.

AstraZeneca fell more than 10%, and GSK almost 4% by late afternoon

in London.

Dr Graham's warning came as he was speaking to the US Senate on

Thursday on Merck's banned drug Vioxx.

During his talk he cast doubt on the FDA's competence.

Dr Graham's list of drugs requiring further scrutiny from the Food

and Drug Administration included AstraZeneca's Crestor,

GlaxoKline's Serevent and Roche's Accutane.

In response, AstraZeneca said during Friday afternoon: " We have been

assured today at senior levels in the FDA that there is no concern

in relation to Crestor's safety " .

Glaxo says its quest is to " enable people to do more,

feel better and live longer "

Merrill Lynch, the US investment bank, noted that neither asthma

drug, Serevent, nor acne drug, Accutane, accounted for a big share

of their makers' profits.

But it expects cholesterol-cutting Crestor to make up 12% of

AstraZeneca's sales by 2008.

A forthcoming article in the US American Medical Association Review

is expected to cover the drug's kidney side-effects.

Safe and effective

Unethical behaviour by drug companies has been in the spotlight

after New York attorney general Eliot Spitzer fined GSK for

allegedly suppressing negative clinical trial data on Seroxat.

In a statement issued on Thursday GSK said it stands behind

Serevent, saying it is " safe and effective " .

It added that: " any issues concerning mortality...have been fully

considered by the FDA, resulting in a black box warning that was

included in the medicine's label " in August 2003.

http://news.bbc.co.uk/1/hi/business/4025001.stm

[Guest guest]

http://www.network54.com/Forum/message?

forumid=281849 & messageid=1100892378

Drug firms hit by safety scares

Concerns about the health of drug companies after a warning from a

whistleblower at the US Food and Drug Administration (FDA) have hit

shares.

The FDA's Dr Graham warned that certain drugs from

AstraZeneca, Roche and GlaxoKline (GSK) needed further

regulatory attention.

AstraZeneca responded during the afternoon on Friday by insisting

the FDA had said it had no safety concerns.

AstraZeneca fell more than 10%, and GSK almost 4% by late afternoon

in London.

Dr Graham's warning came as he was speaking to the US Senate on

Thursday on Merck's banned drug Vioxx.

During his talk he cast doubt on the FDA's competence.

Dr Graham's list of drugs requiring further scrutiny from the Food

and Drug Administration included AstraZeneca's Crestor,

GlaxoKline's Serevent and Roche's Accutane.

In response, AstraZeneca said during Friday afternoon: " We have been

assured today at senior levels in the FDA that there is no concern

in relation to Crestor's safety " .

Glaxo says its quest is to " enable people to do more,

feel better and live longer "

Merrill Lynch, the US investment bank, noted that neither asthma

drug, Serevent, nor acne drug, Accutane, accounted for a big share

of their makers' profits.

But it expects cholesterol-cutting Crestor to make up 12% of

AstraZeneca's sales by 2008.

A forthcoming article in the US American Medical Association Review

is expected to cover the drug's kidney side-effects.

Safe and effective

Unethical behaviour by drug companies has been in the spotlight

after New York attorney general Eliot Spitzer fined GSK for

allegedly suppressing negative clinical trial data on Seroxat.

In a statement issued on Thursday GSK said it stands behind

Serevent, saying it is " safe and effective " .

It added that: " any issues concerning mortality...have been fully

considered by the FDA, resulting in a black box warning that was

included in the medicine's label " in August 2003.

http://news.bbc.co.uk/1/hi/business/4025001.stm